US headquartered Aucta Pharmaceuticals, Inc., a technology based company focusing on the development and commercialization of Branded Specialty Products, has announced that the Company has entered into an exclusive license agreement with Jiangsu Wanbang Biopharmaceuticals Group Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., to license its China marketing rights for its U.S. FDA approved Vigabatrin for Oral Solution.
